Edwards Lifesciences Corporation

(New York Stock Exchange)
Back to all articles
Bullish +55

Diversified Trust Co Decreases Holdings in Edwards Lifesciences ...

AI-generated analysis

πŸ“‰ Diversified Trust Co decreased its EW holdings by 45.7% in Q1, reducing its stake to 20,057 shares valued at $1.6 million.

πŸ“ˆ Multiple new institutional investors entered positions in Q4, including JPL Wealth Management ($25k), MV Capital ($26k), and Kohmann Bosshard ($28k).

πŸ’° VP Donald E. Bobo, Jr. sold 23,145 shares for $2 million on May 27th, reducing his personal ownership by 19%.

πŸ“‰ CFO Scott B. Ullem sold 13,000 shares for $1.04 million in April under a Rule 10b5-1 trading plan.

πŸ“Š Insiders have collectively sold 81,038 shares worth $6.7 million over the last ninety days.

πŸ† The company beat Q1 earnings estimates with $0.78 EPS and revenue of $1.65 billion, a 16.7% increase from the prior year.

πŸ“ˆ Edwards Lifesciences raised FY 2026 guidance to an EPS range of $2.95-$3.05.

πŸ’΅ The stock trades at a PE ratio of 45.59 with a market capitalization of $49.36 billion.

πŸ›‘οΈ Financial health remains strong with a current ratio of 4.42 and a debt-to-equity ratio of only 0.06.

Bullish Signals
  • Edwards Lifesciences beat Q1 analyst estimates, reporting $0.78 EPS compared to the consensus of $0.73.
  • Revenue grew 16.7% year-over-year to reach $1.65 billion, exceeding expectations of $1.60 billion.
  • The company provided forward guidance for FY 2026 EPS between $2.95 and $3.05, aligning with or slightly beating analyst consensus.
  • Strong balance sheet metrics include a current ratio of 4.42 and a negligible debt-to-equity ratio of 0.06.
  • New institutional capital is flowing in from multiple funds including JPL Wealth Management and MV Capital Management.
Risk Factors
  • Diversified Trust Co, a significant holder, reduced its position by 45.7% during the first quarter.
  • Executive insiders have sold a substantial amount of stock recently, with VP Bobo selling $2 million worth and CFO Ullem selling $1 million worth.
  • Total insider selling over the last ninety days reached $6.7 million, representing a 0.31% ownership stake remaining for executives.
Full Analysis
Diversified Trust Co significantly reduced its position in Edwards Lifesciences Corporation (NYSE:EW) by 45.7% during the first quarter, selling 16,910 shares to hold a remaining stake of 20,057 shares valued at $1.6 million. While Diversified Trust exited substantially, several other institutional investors including JPL Wealth Management, MV Capital Management, and Kemnay Advisory Services initiated new positions in the fourth quarter, with stakes ranging from approximately $25,000 to $28,000 each. Insider trading activity shows a notable reduction in executive ownership. VP Donald E. Bobo, Jr. sold 23,145 shares for roughly $2 million on May 27th, while CFO Scott B. Ullem sold 13,000 shares for about $1 million in April under a pre-arranged trading plan. Collectively, insiders have sold over 81,000 shares worth approximately $6.7 million in the last ninety days, leaving them with just 0.31% of the company's stock. Financially, Edwards Lifesciences reported strong quarterly results on April 23rd, beating analyst estimates with earnings per share of $0.78 versus a consensus of $0.73 and revenue of $1.65 billion, up 16.7% year-over-year. The company maintains robust balance sheet metrics with a current ratio of 4.42 and minimal debt, while providing FY 2026 EPS guidance between $2.95 and $3.05. Analysts currently expect full-year earnings of $3.00.